Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L)
Sponsor: Samsung Medical Center
Summary
A single institution with a single group, a phase II study, low- and medium-risk studies performed after biodegradable substance injection prostate cancer dosage increase. The investigator plans to evaluate grade 1 or higher rectal bleeding occurring within 3 years in patients who have received low -fractionation curative radiotherapy.
Key Details
Gender
MALE
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
33
Start Date
2023-08-11
Completion Date
2033-12-31
Last Updated
2024-06-21
Healthy Volunteers
No
Interventions
Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.
this researcher used a biodegradable material injection technique. after subdivision radical received radiation therapy We plan to conduct a phase II clinical study to evaluate the safety of prostate cancer patients.
Locations (1)
Samsung Medical Center
Seoul, South Korea